CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Allopurinol +1 moredrug
Likely dose
Allopurinol 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00643123
NCT00643123Phase 4Completed
CompareCT.gov

A Double-Blind, Placebo Controlled Augmentation Study With Allopurinol for Treatment Resistant Mania

Cedars-Sinai Medical Center·interventional·Posted Mar 26, 2008·Updated May 8, 2019

In Brief

A Phase 4 clinical trial evaluating Allopurinol and Placebo for Bipolar Disorder and 2 related conditions. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate the efficacy of allopurinol as an augmentation agent for treatment resistant mania and mixed mania.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBipolar Disorder, Mixed Mania, Treatment-Resistant Mania
CountriesUnited States
CollaboratorsNational Alliance for Research on Schizophrenia and Depression

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 26, 2008
Enrollment StartSep 1, 2007
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 18.3 years ago

Interventions

Allopurinoldrug

300-600 mg/day over a 6 week period

Placeboother

Inactive substance